What is the history of Degos Disease?

Degos disease, also known as malignant atrophic papulosis, was first described in 1941 by Robert Degos and colleagues as a rare vasculopathy characterized by distinctive porcelain-white skin lesions. While originally thought to be a purely dermatological condition, medical understanding has evolved to recognize Degos disease as a systemic, life-threatening process involving small-vessel occlusion that can affect the gastrointestinal tract and central nervous system.

Who first discovered Degos disease?

The condition was officially characterized in 1941 by French dermatologist Robert Degos, along with his colleagues Delort and Tricot. They identified the pathognomonic skin lesions—small, reddish papules that develop a porcelain-white center—which remain the primary clinical hallmark used to identify Degos disease today.

How has our understanding of Degos disease evolved?

For decades, clinicians debated whether Degos disease was a primary skin disorder or a systemic inflammatory condition. By the mid-20th century, autopsy reports confirmed that the underlying mechanism is a thrombotic vasculopathy, where small-to-medium-sized arteries become occluded. We now classify Degos disease into two forms: a benign form limited to the skin and a systemic form that can cause fatal bowel perforation or neurological complications.

What are the major milestones in managing Degos disease?

Historically, treatments were purely empirical and often ineffective. Modern medicine has shifted toward aggressive management of the thrombotic process. Key developments include:

• Early Era: Surgical intervention was the only option for bowel perforations caused by Degos disease.


• Pharmacological Advances: Introduction of antiplatelet and anticoagulant therapies to mitigate microvascular clotting.


• Modern Therapies: The use of terminal complement inhibitors, such as eculizumab, has shown promise in slowing the progression of systemic Degos disease in select cases.

How has patient advocacy changed the landscape?

Because Degos disease is exceptionally rare, patient-led initiatives have been vital for progress. At DiseaseMaps.org, 18 people with Degos disease have joined our community to share their experiences, helping researchers aggregate data that would otherwise be impossible to collect. This collective advocacy has accelerated the creation of international registries, allowing scientists to study the natural history of the condition more effectively than ever before.

Next steps

• Consult a specialized rheumatologist or dermatologist with experience in rare vasculitis.


• Connect with the 18 community members on DiseaseMaps.org to share resources.


• Monitor for early gastrointestinal symptoms, which remain a primary concern for systemic progression.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Degos Disease.


• Orphanet: Malignant atrophic papulosis.


• OMIM (Online Mendelian Inheritance in Man): Degos Disease entry.


• The Degos Disease Support Network (Patient Advocacy Group).